claes

/Claes Holmberg

About Claes Holmberg

This author has not yet filled in any details.
So far Claes Holmberg has created 167 blog entries.

EMOTRA AB: Resolution on a new rights issue of shares for continued market introduction of EDOR®

Today, November 1, 2018, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new rights issue of shares. This rights issue will comprise a maximum of 23,978,953 shares and the public has also been invited to participate.   181101 - Emotra- PM - Issue resolution

By | November 6th, 2018|INVESTORS|Comments Off on EMOTRA AB: Resolution on a new rights issue of shares for continued market introduction of EDOR®

Management changes at EMOTRA

Emotra’s CEO announces that he is stepping down. Emotra’s board of directors has appointed Marketing Manager Daniel Poté as the new CEO. Daniel will assume this new position immediately. Margit Ferm has stated that she wishes to step down as chairperson of the board, but will continue her engagement as a board member. Claes Holmberg [...]

By | October 24th, 2018|INVESTORS|Comments Off on Management changes at EMOTRA

EMOTRA announces that a German psychiatric hospital is introducing EDOR

Yesterday, on October 17, 2018, Emotra hosted a training seminar for doctors and test leaders at a number of clinics that belong to a German psychiatric and psychotherapeutic hospital. This training is the start of a controlled introduction of the test in their clinical practice. The hospital will borrow hardware from us during a defined [...]

By | October 19th, 2018|INVESTORS|Comments Off on EMOTRA announces that a German psychiatric hospital is introducing EDOR

Important developments for Emotra

Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the Company was recently invited by one of Great Britain’s leading chains [...]

By | October 1st, 2018|INVESTORS|Comments Off on Important developments for Emotra

New publication demonstrates the strength of Emotra’s test, EDOR®

A study conducted by Emotra’s Chief of Research and the inventor of EDOR®, Lars-Håkan Thorell, and the biostatistician Karl Wahlin demonstrates how strongly the company’s test identifies patients at risk of committing suicide.   180904- Emotra - PM - New publication demonstrates the strength of EDOR tests

By | September 4th, 2018|INVESTORS|Comments Off on New publication demonstrates the strength of Emotra’s test, EDOR®

Emotra is granted a patent in Japan

As we have previously announced, Japan is one of Emotra’s high-priority markets. The company has applied for patents in the EU, USA, Canada and Japan. The Japanese patent office has now informed us that Emotra’s Japanese patent application number 2016-516080 has been approved.   180730- Emotra - PM - Patent approved in Japan

By | July 30th, 2018|INVESTORS|Comments Off on Emotra is granted a patent in Japan

Emotra focuses on Europe’s largest cities

As we notified in a previous newsletter and our annual report, Emotra has changed its market introduction strategy for EDOR®. In the first and second quarter of 2018, we have been working the markets more directly and with a greater geographical focus. Given the company’s resources and previous experience, we have chosen to focus our [...]

By | July 5th, 2018|INVESTORS|Comments Off on Emotra focuses on Europe’s largest cities